Author/Authors :
Ebrahimi ، Mehdi Internal Medicine Department - School of Medicine, Sina Hospital - Tehran University of Medical Sciences , Namazi Shabestari ، Alireza Department of Geriatric Medicine - School of Medicine - Tehran University of Medical Sciences , Ahmadi ، Navid , Mashhadi ، Rahil Department of Biology - Khatam University , Hosseini ، Fatemeh Department of Cellular and Molecular Biology - School of Biology, College of Science - University of Tehran , Zahmatkesh ، Parisa Department of Genetics - Islamic Azad University, Medical Branch , Zareian Baghdadabad ، Leila Department of Biology - Medical Biotechnology Research Center - Yazd University , Khajavi ، Alireza Faculty of Paramedical Sciences - Shahid Beheshti University of Medical Sciences , Mesbah ، Gholamreza Department of Pathology - AshianGanoTeb Biopharmaceutical Company - Golestan University of Medical Sciences , Raouf Sarshoori ، Javad Department of Anatomy - Faculty of Medicine - Baqiyatallah University of Medical Sciences , Khoshchehreh ، Mahdi Department of Pathology - University of California , Homayoun ، Hassan Department of Electrical and Computer Engineering - University of Kashan , Noori ، Maryam Student Research Committee, School of Medicine - Iran University of Medical Sciences , Rahimnia ، Ramin Department of Medical Nanotechnology - School of Advanced Technologies in Medicine - Tehran University of Medical Sciences , Nikoobakht ، Mohammadreza Department of Urology - Sina Hospital - Tehran University of Medical Sciences
Abstract :
Introduction: We aimed to evaluate whether Liraglutide can remove the deteriorating impact of a high-fat diet (HF) diet on the genitourinary system.Methods: Fifty-six C57 mice were recruited of which received an HF as the intervention group, and a chow diet (CH) as a control group. After two months the case group was sub-grouped into three groups; 1: group HF with a daily injection of 0.4mg/kg liraglutide (HF+Lir), 2: CH with a daily injection of 0.4mg/kg liraglutide (CH+Lir), and 3: HF diet with an infusion of normal saline (HF+NS). After two months, all mice were sacrificed for additional testing.Results: Serological analysis showed no significant difference for lipid profile (P-value 0.05) and hormones except for PSA in males (P-value=0.019). This significance was seen when comparing CH+Lir and HF+NS to the control group (P-values=0.014 and 0.025, respectively). Liraglutide decreases testosterone in both genders and adiponectin and insulin in males. Total sperm count was decreased, and the difference between the groups was significant (P-value=0.013).Conclusions: Liraglutide cannot recover the deteriorating impact of an HF diet on sperm morphology and motility but can improve the sperm DFI and the total number of sperm.
Keywords :
Liraglutide , Urogenital System , Reproductive system , sperm count
